サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1578327

発作性夜間ヘモグロビン尿症（PNH）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 170 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
発作性夜間ヘモグロビン尿症（PNH）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

発作性夜間ヘモグロビン尿症（PNH）治療市場の世界需要は、2023年の44億9,000万米ドルから2032年にはほぼ123億8,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは11.92%です。

発作性夜間ヘモグロビン尿症（PNH）は、慢性血液疾患、すなわち主に血液に影響を及ぼす疾患です。骨髄幹細胞の超希少疾患であり、世界中で2万人以上が罹患しています。この病気は男女に関係なく発症します。身体症状はどの年齢でも起こりうるが、通常は30～40歳の間に発症します。PNH患者の唯一の根治療法は同種幹細胞移植です。

市場力学

多くの血液・骨髄関連疾患の増加と高齢人口の増加が、PNH治療市場の成長を促す主な要因です。これに加えて、生物学的製剤の出現と新規治療薬の採用が市場成長をさらに後押ししています。しかし、現在利用可能な治療に伴う副作用、医療機器のコスト上昇、特に幹細胞移植に必要な手術機器は、PNHの市場成長を抑制するいくつかの要因です。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、発作性夜間ヘモグロビン尿症（PNH）治療の世界市場における各セグメントを包括的に評価することもできます。発作性夜間血色素尿症（PNH）治療業界の成長と動向は、この研究に全体的なアプローチを提供します。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 発作性夜間ヘモグロビン尿症（PNH）治療- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：治療タイプ別

  • 概要
  • 実績および予測データ分析
  • 補体阻害薬
  • 鉄療法
  • 免疫抑制剤
  • 骨髄移植
  • その他の治療タイプ

第6章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：投与経路別

  • 概要
  • 実績および予測データ分析
  • 経口
  • 非経口

第7章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：年齢層別

  • 概要
  • 実績および予測データ分析
  • 小児
  • 成人

第8章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：最終用途別

  • 概要
  • 実績および予測データ分析
  • 病院
  • 専門クリニック
  • 在宅医療
  • その他のエンドユーザー

第9章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 発作性夜間ヘモグロビン尿症（PNH）治療企業の競合情勢

  • 発作性夜間ヘモグロビン尿症（PNH）治療市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Children'S National Hospital
  • F. Hoffmann-La Roche Ltd.
  • Memorial Sloan Kettering Cancer Center
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • UCLA Health
  • University Of Rochester Medical Center
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route Of Administration
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-Use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Other Treatment Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other End-Users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11210464

The global demand for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is presumed to reach the market size of nearly USD 12.38 Billion by 2032 from USD 4.49 Billion in 2023 with a CAGR of 11.92% under the study period 2024-2032.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a chronic hematological disorder, i.e. disorder which primarily affects the blood. It is an ultra-rare disease of bone marrow stem cells which affects more than 20,000 people globally. This disease affects men and women equally. Physical symptoms can begin at any age, they usually develop between 30-40 years of age. The only curative therapy for PNH patients is allogeneic stem cell transplantation.

MARKET DYNAMICS

The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. The growth and trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Other Treatment Types

By Route Of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-Use

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other End-Users
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market include Amgen Inc., Apellis Pharmaceuticals Inc., AstraZeneca Plc, Children'S National Hospital, F. Hoffmann-La Roche Ltd., Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., UCLA Health, University Of Rochester Medical Center. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By End-Use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
  • 5.4. Iron Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
  • 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
  • 5.7. Other Treatment Types Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route Of Administration
  • 6.2. Historical and Forecast Data Analysis By Route Of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. Pediatric Historic and Forecast Sales By Regions
  • 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-Use
  • 8.2. Historical and Forecast Data Analysis By End-Use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare Settings Historic and Forecast Sales By Regions
  • 8.6. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. AstraZeneca Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Children'S National Hospital
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Memorial Sloan Kettering Cancer Center
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Novartis AG
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Regeneron Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Teva Pharmaceuticals Industries Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCLA Health
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. University Of Rochester Medical Center
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies